This HTML5 document contains 33 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n6http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n22http://linked.opendata.cz/resource/AHFS/
n19http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00090/identifier/uniprotkb/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00090/identifier/genbank/
n4http://linked.opendata.cz/resource/drugbank/dosage/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00090/identifier/pharmgkb/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00090/identifier/wikipedia/
n21http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n17http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n23http://linked.opendata.cz/resource/drugbank/medicinal-product/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00090/identifier/drugbank/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n18http://www.drugs.com/cdi/
n20http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10http://linked.opendata.cz/resource/atc/
n9http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00090
rdf:type
n3:Drug
n3:description
Human recombinant alpha-L-iduronidase, 628 residues (mature form), produced by recombinant DNAtechnology in a Chinese hamster ovary cell line. Laronidase is a glycoprotein with a molecular weight of approximately 83 kD. The predicted amino acid sequence of the recombinant form, as well as the nucleotide sequence that encodes it, are identical to a polymorphic form of human a-L-iduronidase. It contains 6 N-linked oligosaccharide modification sites.
n3:dosage
n4:271B443A-363D-11E5-9242-09173F13E4C5 n4:271B4439-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Clarke LA, Wraith JE, Beck M, Kolodny EH, Pastores GM, Muenzer J, Rapoport DM, Berger KI, Sidman M, Kakkis ED, Cox GF: Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics. 2009 Jan;123(1):229-40. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/19117887 # Landry Y, Gies JP: Drugs and their molecular targets: an updated overview. Fundam Clin Pharmacol. 2008 Feb;22(1):1-18. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/18251718
n3:group
approved
n3:halfLife
1.5-3.6 hrs
n3:indication
For the treatment of mucopolysaccharidosis
owl:sameAs
n17:DB00090 n21:DB00090
dcterms:title
Laronidase
adms:identifier
n8:M74715 n11:P35475 n12:DB00090 n14:Laronidase n15:PA164776670
n3:mechanismOfAction
Laronidase catalyses the hydrolysis of terminal alpha-L-iduronic acid residues of dermatan sulfate and heparin sulfate.
n3:packager
n19:271B4437-363D-11E5-9242-09173F13E4C5 n19:271B4435-363D-11E5-9242-09173F13E4C5 n19:271B4436-363D-11E5-9242-09173F13E4C5
n3:synonym
Alpha-L-iduronidase precursor
n9:hasAHFSCode
n22:44-00-00
foaf:page
n6:aldurazyme.htm n18:laronidase.html
n3:Molecular-Formula
n20:271B443E-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n20:271B443D-363D-11E5-9242-09173F13E4C5
n9:hasATCCode
n10:A16AB05
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
210589-09-6
n3:category
n3:containedIn
n23:271B4438-363D-11E5-9242-09173F13E4C5
n3:Hydrophobicity
n20:271B443B-363D-11E5-9242-09173F13E4C5
n3:Isoelectric-Point
n20:271B443C-363D-11E5-9242-09173F13E4C5